News & Updates
Filter by Specialty:
Hydrochlorothiazide use poses risk of cutaneous squamous cell carcinoma among diabetics
Type 2 diabetes (T2D) patients exposed to hydrochlorothiazide for more than 2 years appear to be at higher risk of cutaneous squamous cell carcinoma (cSCC), as reported in a recent study.
Hydrochlorothiazide use poses risk of cutaneous squamous cell carcinoma among diabetics
09 Nov 2021
Omeprazole helps inhibit fatty acid synthase activity in triple-negative breast cancer
Fatty acid synthase (FASN) is commonly expressed in operable triple-negative breast cancer (TNBC) and is associated with a poor prognosis, but omeprazole can hamper FASN activity, which may potentially boost the efficacy of neoadjuvant chemotherapy, according to the results of a phase II study.
Omeprazole helps inhibit fatty acid synthase activity in triple-negative breast cancer
08 Nov 2021
Quadruple therapy with empagliflozin/dapagliflozin affords long-term glycaemic control
A four-drug combination that includes either empagliflozin or dapagliflozin helps keep glucose in check through 3 years for patients with type 2 diabetes (T2D), in addition to its positive effect on weight and tolerable safety profile, as shown in an open-label randomized controlled study.
Quadruple therapy with empagliflozin/dapagliflozin affords long-term glycaemic control
08 Nov 2021
Novel tenofovir formulation noninferior to disoproxil fumarate in chronic hepatitis B
In the treatment of patients with chronic hepatitis B (CHB), the novel tenofovir amibufenamide (TMF) is as good as tenofovir disoproxil fumarate (TDF) in terms of efficacy but with the advantage of better bone and renal safety, according to the results of a noninferiority trial.
